Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

7.4K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.4K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

493
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
493
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

11.2K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
11.2K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

6.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.0K
Protein-protein Interfaces02:04

Protein-protein Interfaces

12.4K
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
12.4K
Transducer Mechanism: G Protein–Coupled Receptors01:30

Transducer Mechanism: G Protein–Coupled Receptors

1.8K
G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical,...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Design and synthesis of an erdafitinib-based selective FGFR2 degrader.

Beilstein journal of organic chemistry·2026
Same author

Engineered VPg saRNA achieves cap-independent, low-immunogenic and precise encoding of therapeutic proteins in vivo.

Nature communications·2026
Same author

Tmem110 regulates the conformation of TRPML1 to maintain endolysosomal homeostasis and prevent mitochondrial DNA leakage and pathological self-DNA processing.

Nature communications·2026
Same author

Fisetin Attenuates Lipopolysaccharide-Induced Acute Lung Injury by Targeting Myeloid Differentiation Factor 88.

Inflammation·2026
Same author

Corrigendum to "Bicyclol ameliorates nonalcoholic fatty liver disease in mice via inhibiting MAPKs and NF-κB signaling pathways" [Biomed. Pharmacother. 141 (2021) 1-12/111874].

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2025
Same author

FGF4-FGFR1 signaling promotes podocyte survival and glomerular function to ameliorate diabetic kidney disease in male mice.

Nature communications·2025

Related Experiment Video

Updated: May 30, 2025

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
06:26

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Published on: May 16, 2021

4.7K

FGF-based drug discovery: advances and challenges.

Gaozhi Chen1, Lingfeng Chen2, Xiaokun Li3

  • 1School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China.

Nature Reviews. Drug Discovery
|January 28, 2025
PubMed
Summary

Fibroblast growth factors (FGFs) are key regulators of human development and metabolism. Recent insights into paracrine FGF signaling mechanisms reveal potential for treating metabolic diseases.

More Related Videos

A Manual Small Molecule Screen Approaching High-throughput Using Zebrafish Embryos
07:45

A Manual Small Molecule Screen Approaching High-throughput Using Zebrafish Embryos

Published on: November 8, 2014

17.5K
Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
07:32

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

7.6K

Related Experiment Videos

Last Updated: May 30, 2025

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
06:26

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Published on: May 16, 2021

4.7K
A Manual Small Molecule Screen Approaching High-throughput Using Zebrafish Embryos
07:45

A Manual Small Molecule Screen Approaching High-throughput Using Zebrafish Embryos

Published on: November 8, 2014

17.5K
Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
07:32

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

7.6K

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Drug Development

Background:

  • The fibroblast growth factor (FGF) family includes 15 paracrine and 3 endocrine polypeptides crucial for development, metabolism, and tissue homeostasis.
  • While endocrine FGFs (e.g., FGF19, FGF21) show therapeutic promise for liver and metabolic diseases, paracrine FGFs have faced development challenges.
  • Paracrine FGFs, despite past failures in areas like wound healing, are regaining interest due to their newly recognized hormone-like metabolic activities.

Purpose of the Study:

  • To explore the therapeutic potential of paracrine fibroblast growth factors (FGFs) for metabolic diseases.
  • To highlight recent advancements in understanding FGF signaling specificity and its implications for drug development.

Main Methods:

  • Review of existing literature on fibroblast growth factor (FGF) family functions.
  • Analysis of recent structural and mechanistic studies on FGF cell surface signaling.
  • Evaluation of the 'threshold model' for FGF signaling specificity.

Main Results:

  • Paracrine FGFs exhibit previously unrecognized FGF hormone-like metabolic activities.
  • Structural elucidation of FGF signaling machinery provides new insights.
  • A novel threshold model explains FGF signaling specificity.

Conclusions:

  • The understanding of paracrine FGFs has shifted, revealing their potential beyond traditional applications.
  • Recent breakthroughs in FGF signaling mechanisms pave the way for developing novel therapies.
  • Paracrine FGFs represent a promising, yet previously overlooked, therapeutic avenue for metabolic diseases.